Bicara Therapeutics BCAX Non-cash lease expense
Non-cash lease expense at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept bcax:OperatingLeaseRightOfUseAssetPeriodicReductionIncludingAdjustments.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's non-cash lease expense?
- Bicara Therapeutics (BCAX) reported non-cash lease expense of $223.75K in Q4 2025.
- How has Bicara Therapeutics's non-cash lease expense changed year-over-year?
- Bicara Therapeutics's non-cash lease expense increased by 1262.3% year-over-year, from -$19.25K to $223.75K.
- What does non-cash lease expense mean?
- The non-cash expense recognized over the term of an operating lease, representing the systematic reduction of the right-of-use asset. This metric is essential for understanding the true operational cost of leased facilities or equipment without the immediate cash impact. It allows for a more accurate assessment of recurring operational overhead.